1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Alvotech Adalimumab Biosimilar Switching Study Hits Key Date

Icelandic Firm Chasing First High-Concentration Adalimumab Biosimilar

 
• By Dean Rudge

Alvotech underlined that it could “save US consumers and taxpayers billions annually,” after hitting a key landmark in its Phase III switching study for its high concentration 100mg/ml biosimilar Humira product.

Chess
Alvotech has taken a key strategic step • Source: Shutterstock

Alvotech is celebrating primary completion of the company’s landmark Phase III clinical switching study for its proposed high-concentration biosimilar version of Humira (adalimumab), with top-line results expected later this year.

The Icelandic firm said it was “the only known company that has both developed a biosimilar candidate for the higher-concentration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products